WO2008153790A3 - Methods of modulating inflammation and compositions therefore - Google Patents

Methods of modulating inflammation and compositions therefore Download PDF

Info

Publication number
WO2008153790A3
WO2008153790A3 PCT/US2008/006728 US2008006728W WO2008153790A3 WO 2008153790 A3 WO2008153790 A3 WO 2008153790A3 US 2008006728 W US2008006728 W US 2008006728W WO 2008153790 A3 WO2008153790 A3 WO 2008153790A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sil
compositions
study
complex
Prior art date
Application number
PCT/US2008/006728
Other languages
French (fr)
Other versions
WO2008153790A2 (en
Inventor
Fred Finkelman
Marat Khodoun
Marsha Willis-Karp
Christina Lewis
Original Assignee
Univ Cincinnati
Fred Finkelman
Marat Khodoun
Marsha Willis-Karp
Christina Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati, Fred Finkelman, Marat Khodoun, Marsha Willis-Karp, Christina Lewis filed Critical Univ Cincinnati
Priority to CA2688256A priority Critical patent/CA2688256A1/en
Priority to EP08767898A priority patent/EP2162743A4/en
Publication of WO2008153790A2 publication Critical patent/WO2008153790A2/en
Publication of WO2008153790A3 publication Critical patent/WO2008153790A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the invention include modulating an IL-13/sIL-13Rα2 complex and methods of modulating expression of various nucleotide sequences of interest including Pira1, Vannin1 and ApoA1. In an aspect, the methods of the invention allow detection of an altered IL-13/sIL-13Rα2 complex level in a subject. Further aspects of the invention allow for identification of subjects suitable for inclusion in a sIL-13Rα2 related study or inflammatory related disorder study.
PCT/US2008/006728 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore WO2008153790A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2688256A CA2688256A1 (en) 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore
EP08767898A EP2162743A4 (en) 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93209507P 2007-05-29 2007-05-29
US60/932,095 2007-05-29

Publications (2)

Publication Number Publication Date
WO2008153790A2 WO2008153790A2 (en) 2008-12-18
WO2008153790A3 true WO2008153790A3 (en) 2009-03-05

Family

ID=40130387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006728 WO2008153790A2 (en) 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore

Country Status (3)

Country Link
EP (1) EP2162743A4 (en)
CA (1) CA2688256A1 (en)
WO (1) WO2008153790A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948770B1 (en) * 2013-01-23 2020-11-18 Institut National de la Santé et de la Recherche Médicale Number of il4 and/or il3 secreting t-cells as a biomarker for allergic diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219149A1 (en) * 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
US20060073148A1 (en) * 2004-06-17 2006-04-06 Wyeth IL-13 binding agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512942A (en) * 1998-12-14 2004-01-30 Univ Johns Hopkins Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors
US20040247524A1 (en) * 2003-06-05 2004-12-09 Philippe Naquet Method of treatment of an inflammatory disorder with a Vanin-1 antagonist
JP2005095166A (en) * 2003-08-28 2005-04-14 Sumitomo Pharmaceut Co Ltd Disease marker of inflammatory bowel disease and utilization of the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219149A1 (en) * 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
US20060073148A1 (en) * 2004-06-17 2006-04-06 Wyeth IL-13 binding agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2162743A4 *

Also Published As

Publication number Publication date
EP2162743A4 (en) 2010-07-14
CA2688256A1 (en) 2008-12-18
WO2008153790A2 (en) 2008-12-18
EP2162743A2 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008152656A3 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
EP1897051A4 (en) Method and system for identifying users and detecting fraud by use of the internet
WO2012054638A3 (en) Nmr systems and methods for the detection of analytes
WO2008127290A3 (en) Alginate and alginate lyase compositions and methods of use
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2008027428A3 (en) Gene expression profiling for identification, monitoring and treatment of transplant rejection
WO2011156734A3 (en) Method of characterizing vascular diseases
WO2007048067A3 (en) C-kit oncogene mutations in melanoma
BRPI0811490A2 (en) COLORIMETRIC METHOD AND CASE OF DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES THROUGH FUNCTIONALIZED METAL NANOPARTICULES WITH MODIFIED OLIGONUCLEOTIDS.
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
DE112007001034T8 (en) Temperature probe and method of making the same
WO2008122053A3 (en) Compositions, kits and related methods for the detection and/or monitoring of pseudomonas aeruginosa
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
WO2006092610A3 (en) Markers for melanoma
WO2010046648A3 (en) Diagnostic test for streptococcus equi
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2009013350A3 (en) Imaging medium comprising hyperpolarised 13 c-lactate and use thereof
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
ITPI20060094A1 (en) EQUIPMENT FOR THE EVALUATION OF THE VISUAL ACUITY OF AN INDIVIDUAL.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08767898

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2688256

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008767898

Country of ref document: EP